Overview

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether adding vorolanib to atezolizumab will improve the length of time that participants are cancer-free after receiving standard chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Xcovery Holding Company, LLC
Treatments:
Atezolizumab
Vorolanib